Summary

For the first time, children ages 8 to 17 who are newly diagnosed with type 1 diabetes have access to an approved treatment that targets the underlying autoimmune disease, rather than solely managing blood sugar levels with insulin. A national group of clinical trial investigators and pediatric diabetes specialists, led by a physician-scientist at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz, have published practical guidance to help care teams and families navigate this new option.

AI summaries can be wrong sometimes—always verify important details using the source article.